Table 1.

EVOKE trial results for 5 individual domains (mean number of MCIDs achieved), cumulative responder score, and holistic minimal clinically important difference score at 1- to 24-month follow up.

Domains	1-mo (n = 111)	3-mo (n = 111)	6-mo (n = 107)	12-mo (n = 103)	18-mo (n = 97)	24-mo (n = 92)
Pain intensity (VAS overall ≥30%)	2.3 (1.0)	2.5 (0.9)	2.4 (0.8)	2.5 (0.9)	2.5 (0.9)	2.3 (1.0)
HRQoL (EQ-5D-5L index score ≥0.074)	3.3 (2.1)	3.5 (2.3)	3.5 (2.1)	3.2 (2.5)	3.3 (2.2)	3.1 (2.2)
Sleep quality (PSQI global score ≥3)*	1.5 (1.4)	1.7 (1.4)	1.6 (1.4)	1.8 (1.5)	1.5 (1.5)	1.5 (1.5)
Physical function (ODI score ≥10)	2.5 (1.6)	2.9 (1.6)	2.7 (1.4)	2.7 (1.5)	2.6 (1.6)	2.5 (1.4)
Emotional function (POMS TMD score ≥10)†	2.3 (1.7)	2.2 (2.0)	2.3 (2.1)	2.2 (2.1)	2.0 (2.1)	2.0 (2.0)
Cumulative responder score‡	11.1 (5.6)	11.9 (6.2)	11.7 (5.9)	11.5 (6.4)	11.1 (5.9)	10.6 (5.6)
Holistic MCID§	2.4 (1.2)	2.6 (1.3)	2.5 (1.2)	2.5 (1.3)	2.4 (1.2)	2.3 (1.2)

Data presented as means and (standard deviations) of MCIDs achieved.

^*N of patients with baseline impairment for sleep quality that completed follow-up: 1 month (n = 108), 3 months (n = 108), 6 months (n = 104), 12 months (n = 100), 18 months (n = 94), 24 months (n = 89).

^†N of patients with baseline impairment for emotional function that completed follow-up: 1 month (n = 68), 3 months (n = 68), 6 months (n = 67), 12 months (n = 64), 18 months (n = 60), 24 months (n = 58).

^‡Cumulative responder score: the total amount of MCIDs achieved after intervention across all 5 domains impaired at baseline for each individual patient.

^§Holistic MCID: cumulative responder score divided by the number of impaired domains at baseline for each individual patient.

EQ-5D-5L, EuroQol 5-dimension 5-level; HRQoL, health-related quality of life; MCID, minimal clinically important difference; ODI, Oswestry disability index; POMS, profile of mood states; PSQI, Pittsburgh sleep quality index; TMD, total mood disorder; VAS, visual analogue scale.